Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Advanced Solid Neoplasm 2Thrombocytosis 1Thrombocythemia, Essential 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Liver Diseases 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Imatinib Mesylate 5venetoclax 1ruxolitinib 1pevonedistat 1nilotinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypereosinophilic Syndrome × pevonedistat × Clear all
NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡